Prospects for development of a rotavirus vaccine against rotavirus diarrhea in infants and young children

Albert Z. Kapikian, Jorge Flores, Yasutaka Hoshino, Karen Midthun, Mario Gorziglia, Kim Y. Green, Robert M. Chanock, Louis Potash, Stephen D. Sears, Mary Lou Clements, Neal A Halsey, Robert E Black, Irene Perez-Schael

Research output: Contribution to journalArticle

Abstract

Major advances have been made in elucidating the etiologic agents of severe infantile diarrhea, and it is clear that rotaviruses are the single most important etiologic agents. Progress in the development of rotavirus vaccine candidates has also moved swiftly with the “Jennerian” approach, in which a related live, attenuated rotaviruSi, strain from a nonhuman host is used as the immunizing antigen. If this strategy is not effective against all rotavirus serotypes, reassortant rotaviruses hold great promise for the development of a multivalent vaccine. Field trials with the “Jennerian” approach vaccines are under way, and phase 1 trials with the reassortants have been initiated.

Original languageEnglish (US)
Pages (from-to)S539-S546
JournalClinical Infectious Diseases
Volume11
DOIs
StatePublished - 1989
Externally publishedYes

Fingerprint

Rotavirus Vaccines
Rotavirus
Diarrhea
Vaccines
Infantile Diarrhea
Antigens

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Cite this

Kapikian, A. Z., Flores, J., Hoshino, Y., Midthun, K., Gorziglia, M., Green, K. Y., ... Perez-Schael, I. (1989). Prospects for development of a rotavirus vaccine against rotavirus diarrhea in infants and young children. Clinical Infectious Diseases, 11, S539-S546. https://doi.org/10.1093/clinids/11.Supplement_3.S539

Prospects for development of a rotavirus vaccine against rotavirus diarrhea in infants and young children. / Kapikian, Albert Z.; Flores, Jorge; Hoshino, Yasutaka; Midthun, Karen; Gorziglia, Mario; Green, Kim Y.; Chanock, Robert M.; Potash, Louis; Sears, Stephen D.; Clements, Mary Lou; Halsey, Neal A; Black, Robert E; Perez-Schael, Irene.

In: Clinical Infectious Diseases, Vol. 11, 1989, p. S539-S546.

Research output: Contribution to journalArticle

Kapikian, AZ, Flores, J, Hoshino, Y, Midthun, K, Gorziglia, M, Green, KY, Chanock, RM, Potash, L, Sears, SD, Clements, ML, Halsey, NA, Black, RE & Perez-Schael, I 1989, 'Prospects for development of a rotavirus vaccine against rotavirus diarrhea in infants and young children', Clinical Infectious Diseases, vol. 11, pp. S539-S546. https://doi.org/10.1093/clinids/11.Supplement_3.S539
Kapikian, Albert Z. ; Flores, Jorge ; Hoshino, Yasutaka ; Midthun, Karen ; Gorziglia, Mario ; Green, Kim Y. ; Chanock, Robert M. ; Potash, Louis ; Sears, Stephen D. ; Clements, Mary Lou ; Halsey, Neal A ; Black, Robert E ; Perez-Schael, Irene. / Prospects for development of a rotavirus vaccine against rotavirus diarrhea in infants and young children. In: Clinical Infectious Diseases. 1989 ; Vol. 11. pp. S539-S546.
@article{5e756241ea734afba4892b002a2cffdf,
title = "Prospects for development of a rotavirus vaccine against rotavirus diarrhea in infants and young children",
abstract = "Major advances have been made in elucidating the etiologic agents of severe infantile diarrhea, and it is clear that rotaviruses are the single most important etiologic agents. Progress in the development of rotavirus vaccine candidates has also moved swiftly with the “Jennerian” approach, in which a related live, attenuated rotaviruSi, strain from a nonhuman host is used as the immunizing antigen. If this strategy is not effective against all rotavirus serotypes, reassortant rotaviruses hold great promise for the development of a multivalent vaccine. Field trials with the “Jennerian” approach vaccines are under way, and phase 1 trials with the reassortants have been initiated.",
author = "Kapikian, {Albert Z.} and Jorge Flores and Yasutaka Hoshino and Karen Midthun and Mario Gorziglia and Green, {Kim Y.} and Chanock, {Robert M.} and Louis Potash and Sears, {Stephen D.} and Clements, {Mary Lou} and Halsey, {Neal A} and Black, {Robert E} and Irene Perez-Schael",
year = "1989",
doi = "10.1093/clinids/11.Supplement_3.S539",
language = "English (US)",
volume = "11",
pages = "S539--S546",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Prospects for development of a rotavirus vaccine against rotavirus diarrhea in infants and young children

AU - Kapikian, Albert Z.

AU - Flores, Jorge

AU - Hoshino, Yasutaka

AU - Midthun, Karen

AU - Gorziglia, Mario

AU - Green, Kim Y.

AU - Chanock, Robert M.

AU - Potash, Louis

AU - Sears, Stephen D.

AU - Clements, Mary Lou

AU - Halsey, Neal A

AU - Black, Robert E

AU - Perez-Schael, Irene

PY - 1989

Y1 - 1989

N2 - Major advances have been made in elucidating the etiologic agents of severe infantile diarrhea, and it is clear that rotaviruses are the single most important etiologic agents. Progress in the development of rotavirus vaccine candidates has also moved swiftly with the “Jennerian” approach, in which a related live, attenuated rotaviruSi, strain from a nonhuman host is used as the immunizing antigen. If this strategy is not effective against all rotavirus serotypes, reassortant rotaviruses hold great promise for the development of a multivalent vaccine. Field trials with the “Jennerian” approach vaccines are under way, and phase 1 trials with the reassortants have been initiated.

AB - Major advances have been made in elucidating the etiologic agents of severe infantile diarrhea, and it is clear that rotaviruses are the single most important etiologic agents. Progress in the development of rotavirus vaccine candidates has also moved swiftly with the “Jennerian” approach, in which a related live, attenuated rotaviruSi, strain from a nonhuman host is used as the immunizing antigen. If this strategy is not effective against all rotavirus serotypes, reassortant rotaviruses hold great promise for the development of a multivalent vaccine. Field trials with the “Jennerian” approach vaccines are under way, and phase 1 trials with the reassortants have been initiated.

UR - http://www.scopus.com/inward/record.url?scp=0024659961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024659961&partnerID=8YFLogxK

U2 - 10.1093/clinids/11.Supplement_3.S539

DO - 10.1093/clinids/11.Supplement_3.S539

M3 - Article

VL - 11

SP - S539-S546

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

ER -